Tag Archive for: Clinical Development

Bert Slade, MD, Joins Tissue Tech as Vice President, Clinical Development

Former Chief Scientific and Medical Officer Advanced Wound Care, Smith & Nephew

Life Science Partner recruited Bert Slade, MD, to serve as the Vice President, Clinical Development for TissueTech.  Slade has built his career in leading clinical trials, medical affairs, and regulatory approvals for medical device and pharmaceutical companies worldwide.  He joins TissueTech while also providing clinical support for Chisholm Clinical Research Services where he has set up his own vehicle to conduct clinical trials using the European platform as an inroad to EU product approvals.

During his tenure at Smith and Nephew, Slade was challenged as the first CMO for the Advanced Wound Management Division to restructure the three-strategic business unit R&D Departments and two clinical groups into a single international R&D organization with the addition of post-marketing surveillance.

“With his extensive experience in FDA submissions of BLAs and NDAs including a clinical background in wound healing and regenerative medicine, Slade will serve as a critical asset for TissueTech’s clinical trial designs and submissions,” states Tom Callaway, President and Founding Partner of Life Science Partner.

Slade earned his Bachelor of Arts Degree in Biology from Hamilton College.  He earned his MD from the Upstate Medical Center at the University of New York.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Russ Ellison, MD, Senior Pharmaceutical Executive Joins FibroGen as Vice President, Clinical Development

Leading Clinical Development of Novel Compounds for Anemia and Fibrosis

Life Science Partner announced today the recruitment of Russell Ellison, MD, to become Vice President, Clinical and Medical Affairs at FibroGen, a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis and Hypoxia-Inducible Factor (HIF) biology to discover, develop and commercialize novel therapeutics for fibrotic disorders, anemia, ischemic disease, cancer and other areas of unmet medical needs.

FibroGen also develops and produces recombinant human collagens and gelatins using unique production technology that provides the basis for FibroGen’s proprietary cosmetic dermal filler and biomaterials supply business.

“Russ was attracted to FibroGen due to its extensive portfolio of compounds marching steadily toward the clinic and their potential to dramatically improve the lives of patients with anemia and other life-threatening diseases,” said Thomas H. Callaway, MD, Founder and President of Life Science Partner. “His combination of FDA regulatory experience and global medical affairs made him a perfect fit for this emerging pharmaceutical company,” he added.

Prior to his recruitment to FibroGen, Ellison was Vice President, Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo USA, with responsibility for building its best-in-class medical affairs, regulatory and safety teams. He oversaw the clinical development of key products such as Plavix and Ambien, and was renown for reducing project development timelines and improving relations with managed care companies.

Ellison was recruited to Sanofi from Hoffmann La Roche. As Vice President, Medical Affairs and the Chief Medical Officer, he oversaw a 300-member organization that oversaw clinical trials, managed medical strategy, intervened on behalf of the company with regulatory agencies and developed clinical development strategies in sync with the company’s commercial strategies for its compounds in development. He was noted by his peers as a rare physician who understood the business aspects, as well as the clinical implications of the pharmaceutical industry.

A Canadian physician, Ellison has a global understanding of drug development and registration, as well as the challenges of reimbursement and clinical acceptance of new drugs. At FibroGen, his skills will be valuable as he builds the clinical and regulatory teams and moves the products from the pre-clinical to clinical development phase.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Rajesh Malik Chosen To Lead Clinical Development – Adherex

Life Science Partner places pharmaceutical veteran and oncology specialist as chief medical officer

ATLANTA, Georgia – September 7, 2004 – Life Science Partner announces the placement of Rajesh K. Malik, M.B., Ch.B. as chief medical officer at Adherex Technologies, Inc., in Research Triangle Park, North Carolina. With the position, Malik takes responsibility for the clinical development efforts behind Adherex’s growing portfolio of oncology products. He will

guide decisions about clinical utility, formulate regulatory strategies for the U.S. and Europe, lead the clinical trials design team, and promote physician advocacy. A biopharmaceutical company, Adherex discovers and develops cancer therapeutics through its pioneering platform for tumor vascular targeting.

“For Adherex, Raj was an exceptional find,” says Life Science Partner, Founder and President Thomas H. Callaway. “In addition to his original insights into anti-angiogenesis, which is at the core of Adherex’s product portfolio, he has a successful record of regulatory submission on three continents and he fully understands the commercialization process.”

A pediatric oncologist by training, Malik combines experience in cutting-edge academic research with strong business analytical skills and accomplishments in corporate pharmaceutical environments large and small.

Prior to Adherex, Malik was executive director at EMD Pharmaceuticals, a subsidiary of Germany-based Merck KGaA. As part of senior management at EMD, Malik led global project management for single oncology products and served on the company’s combined business and clinical operations team to guide global oncology product strategy.

As associate director at Bristol Myers Squibb, Malik held responsibility for the clinical development strategy for oral taxane worldwide and provided clinical oversight for Erbitux in Europe.

Malik also spent seven years as an assistant professor at the University of Virginia, where his research focused on signal transduction across the interface of integrins and extra cellular matrix.

Malik holds a medical degree from the School of Medicine and Biomedical Sciences at the University of Sheffield, Sheffield, U.K. He is licensed in pediatrics in North Carolina and Virginia.

/0 Comments/by